Fredrik Piehl Selected Research

MHC class II transactivator protein

7/2009	Differential nerve injury-induced expression of MHC class II in the mouse correlates to genetic variability in the type I promoter of C2ta.
3/2008	Vra4 congenic rats with allelic differences in the class II transactivator gene display altered susceptibility to experimental autoimmune encephalomyelitis.
5/2005	MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fredrik Piehl Research Topics

Disease

60	Multiple Sclerosis 11/2022 - 06/2004
17	Relapsing-Remitting Multiple Sclerosis 01/2022 - 01/2015
12	Inflammation (Inflammations) 01/2022 - 10/2003
10	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 07/2009
9	Traumatic Brain Injuries (Traumatic Brain Injury) 12/2021 - 01/2013
7	Psychotic Disorders (Schizoaffective Disorder) 08/2022 - 01/2018
7	Myasthenia Gravis 08/2021 - 03/2016
6	Infections 07/2022 - 01/2012
5	Schizophrenia (Dementia Praecox) 08/2022 - 01/2019
5	Disease Progression 01/2021 - 01/2013
5	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2020 - 10/2003
4	Neuroinflammatory Diseases 12/2021 - 04/2013
3	Normal Pressure Hydrocephalus 01/2021 - 09/2019
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 05/2011
3	Neoplasms (Cancer) 01/2020 - 01/2015
3	Encephalitis (Encephalitis, Rasmussen) 11/2017 - 08/2010
3	Rheumatoid Arthritis 01/2017 - 05/2005
2	COVID-19 01/2022 - 12/2021
2	Wounds and Injuries (Trauma) 12/2021 - 05/2013
2	Autoimmune Diseases of the Nervous System 11/2021 - 03/2015
2	Progressive Multifocal Leukoencephalopathy 05/2021 - 06/2016
2	Cognitive Dysfunction 01/2021 - 11/2019
2	Atrophy 01/2021 - 01/2020
2	Brain Injuries (Brain Injury) 01/2021 - 09/2019
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 12/2020 - 02/2019
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2020 - 01/2018
2	Demyelinating Diseases (Demyelinating Disease) 01/2020 - 01/2020
2	Anti-N-Methyl-D-Aspartate Receptor Encephalitis 02/2019 - 03/2015
2	Nervous System Diseases (Neurological Disorders) 10/2018 - 01/2016
2	Fatigue 01/2018 - 03/2016
2	Hypoxia (Hypoxemia) 01/2017 - 07/2002
2	Central Nervous System Diseases (CNS Diseases) 01/2015 - 02/2014
2	Alzheimer Disease (Alzheimer's Disease) 11/2013 - 01/2013
2	Herpes Simplex 01/2012 - 08/2010
1	Cytomegalovirus Infections (Inclusion Disease) 08/2021
1	Obesity 08/2021

Drug/Important Bio-Agent (IBA)

21	Rituximab (Mabthera)FDA Link 11/2022 - 02/2016
20	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2013
12	Natalizumab (Tysabri)FDA Link 01/2022 - 01/2011
8	Proteins (Proteins, Gene)FDA Link 12/2021 - 04/2013
7	Dimethyl FumarateIBA 01/2022 - 02/2018
6	AutoantibodiesIBA 11/2021 - 06/2017
6	AntibodiesIBA 11/2021 - 02/2015
5	Pharmaceutical PreparationsIBA 11/2022 - 01/2018
5	Fingolimod Hydrochloride (FTY720)FDA Link 01/2022 - 06/2016
5	Polytetrafluoroethylene (Teflon)FDA Link 01/2022 - 01/2019
4	Alemtuzumab (Campath)FDA Link 01/2022 - 01/2020
4	ocrelizumabIBA 01/2022 - 01/2018
4	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 11/2021 - 03/2015
4	CytokinesIBA 01/2019 - 05/2004
3	Glatiramer Acetate (Copaxone)FDA Link 01/2022 - 01/2018
3	insulin receptor-related receptor (IRR)IBA 10/2020 - 01/2015
3	Transcription Factors (Transcription Factor)IBA 01/2020 - 07/2002
3	Complement System Proteins (Complement)IBA 01/2015 - 01/2013
3	MHC class II transactivator proteinIBA 07/2009 - 05/2005
2	InterferonsIBA 01/2022 - 12/2020
2	NeurocanIBA 01/2021 - 09/2019
2	KynurenineIBA 01/2021 - 03/2020
2	AntioxidantsIBA 01/2021 - 01/2015
2	BrevicanIBA 01/2021 - 09/2019
2	Peptides (Polypeptides)IBA 01/2021 - 01/2017
2	Immunoglobulins (Immunoglobulin)IBA 10/2020 - 01/2019
2	Blood Proteins (Serum Proteins)IBA 01/2020 - 10/2019
2	Interferon-betaIBA 01/2020 - 01/2018
2	tocilizumab (atlizumab)FDA Link 11/2019 - 06/2017
2	Retinaldehyde (Retinal)IBA 11/2019 - 01/2017
2	ChemokinesIBA 01/2019 - 10/2003
2	MicroRNAs (MicroRNA)IBA 01/2019 - 06/2016
2	CXC ChemokinesIBA 01/2019 - 01/2013
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2019 - 10/2014
2	Cholinergic ReceptorsIBA 01/2019 - 03/2016
2	SphingolipidsIBA 01/2018 - 09/2015
2	HLA-DRB1 Chains (HLA DRB1)IBA 01/2018 - 01/2016
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2018 - 03/2013
2	ButyrylcholinesteraseIBA 01/2015 - 11/2013
2	C-Type Lectins (C-Type Lectin)IBA 12/2014 - 05/2013
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2011 - 07/2002
2	Myelin-Oligodendrocyte GlycoproteinIBA 03/2008 - 10/2003
1	COVID-19 VaccinesIBA 11/2022
1	Dopamine (Intropin)FDA LinkGeneric 08/2022
1	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 08/2022
1	teriflunomideIBA 01/2022
1	Antidepressive Agents (Antidepressants)IBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	TabletsIBA 01/2022
1	Cladribine FDA LinkGeneric 01/2022
1	siponimodIBA 01/2022
1	ApolipoproteinsIBA 12/2021
1	Serum AlbuminIBA 12/2021
1	Immunomodulating AgentsIBA 09/2021
1	nitazoxanide (NTZ)FDA Link 05/2021
1	BilirubinIBA 01/2021

Therapy/Procedure

18	Therapeutics 01/2022 - 06/2016
3	Stem Cell Transplantation 01/2017 - 02/2015
2	Immunotherapy 11/2021 - 01/2020
2	Activities of Daily Living (ADL) 08/2021 - 01/2019
2	Hematopoietic Stem Cell Transplantation 01/2021 - 02/2015
2	Transplantation 01/2016 - 02/2015
1	Duration of Therapy 11/2022
1	Immunomodulation 07/2022